PCS "Encouraged" By Pricing Of COX-2 Inhibitors Close To Branded NSAIDs

The recent pricing of Merck's Vioxx and Searle's Celebrex close to existing branded non-steroidal anti-inflammatory drugs is evidence of some pricing restraint in the pharmaceutical industry, PCS Health Systems CEO Jean-Pierre Millon said May 3 at The Wall Street Journal Healthcare Summit in Washington, D.C.